VivoSeq
Other

IDH1 Mutation

2

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

IDH1 Mutation is an early-stage landscape with 2 programs across 3 companies. The most active players are Rigel Pharmaceuticals, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, CStone Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rigel Pharmaceuticals

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2C

CStone Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Olutasidenib

Rigel Pharmaceuticals

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Completed1 · 25%

Clinical Trials

Trial Activity

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07282262·300 enrolled
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
Completed·CCStone Pharmaceuticals·Phase 1·NCT04176393·30 enrolled
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Recruiting·RRigel Pharmaceuticals·Phase 4·NCT07486713·16 enrolled
Pilot Single Arm Phase 2 Study of Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Recruiting·—·Phase 2·NCT07471841·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)